Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
ERG rod a-wave in Oguchi disease.
Usui T, Tanimoto N, Ueki S, Takagi M, Hasegawa S, Abe H, Sekiya K, Nakazawa M. Usui T, et al. Among authors: sekiya k. Vision Res. 2004 Mar;44(5):535-40. doi: 10.1016/j.visres.2003.06.003. Vision Res. 2004. PMID: 14680778 Free article.
Metagenomic gut microbiome analysis of Japanese patients with multiple chemical sensitivity/idiopathic environmental intolerance.
Watai K, Suda W, Kurokawa R, Sekiya K, Hayashi H, Iwata M, Nagayama K, Nakamura Y, Hamada Y, Kamide Y, Fukutomi Y, Nakabayashi T, Tanaka K, Kamita M, Taniguchi M, Hattori M. Watai K, et al. Among authors: sekiya k. BMC Microbiol. 2024 Mar 11;24(1):84. doi: 10.1186/s12866-024-03239-y. BMC Microbiol. 2024. PMID: 38468206 Free PMC article.
Uncovering Severe Patient Group With Pollen-Related Extrarespiratory Allergic Symptoms: A Year-Long Diary Survey in Japan.
Fukutomi Y, Tanaka H, Sekiya K, Watai K, Hamada Y, Iwata M, Saito A, Okabe K, Sugiyama A, Fukushima T, Oshikawa C, Uetake H, Yoshisue H, Irie T, Kishikawa R. Fukutomi Y, et al. Among authors: sekiya k. J Allergy Clin Immunol Pract. 2024 Feb 19:S2213-2198(24)00167-3. doi: 10.1016/j.jaip.2024.02.011. Online ahead of print. J Allergy Clin Immunol Pract. 2024. PMID: 38382879 Free article.
A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19.
Hirai T, Asano K, Ito I, Miyazaki Y, Sugiura H, Agirbasli M, Kobayashi S, Kobayashi M, Shimada D, Natsume I, Kawasaki T, Ohba T, Tajiri S, Sakamaki F, Mineshita M, Takihara T, Sekiya K, Tomii K, Tomioka H, Kita H, Nishizaka Y, Fukui M, Miyata T, Harigae H. Hirai T, et al. Among authors: sekiya k. Sci Rep. 2024 Jan 2;14(1):165. doi: 10.1038/s41598-023-50445-1. Sci Rep. 2024. PMID: 38168544 Free PMC article. Clinical Trial.
284 results